TV
Thyagarajan Venkatraman
About Thyagarajan Venkatraman
Data last updated:
Thyagarajan Venkatraman was a Director at Tata Consultancy Services Limited (2005–2018), Director at E.I.D Parry (India) Limited (2004–2007) and Director at Glaxosmithkline Pharmaceuticals Limited (2001–2015), and held 4 more directorships. The companies operate in Information Technology, Agriculture and Pharma.
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 05 Sep 2005 | 1995 | ₹271,423 Cr (FY 2026) | Active | |
| Director | 29 Mar 2004 | 1975 | ₹38,883 Cr (FY 2026) | Active | |
| Director | 01 Jan 2001 | 1924 | ₹3,895 Cr (FY 2025) | Active | |
| Additional Director | 28 Aug 2008 | 1998 | ₹3,582 Cr (FY 2026) | Active | |
| Director | 09 Sep 2015 | 1992 | ₹870 Cr (FY 2025) | Active | |
| Director | 29 Aug 2008 | 2003 | ₹7.17 Cr (FY 2016) | Under Liquidation | |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Thyagarajan Venkatraman
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Thyagarajan Venkatraman
Thyagarajan Venkatraman was first appointed on 01 Jan 2001 as Director at Glaxosmithkline Pharmaceuticals Limited. The most recent appointment on record is 09 Sep 2015 at Healthium Medtech Limited.
Thyagarajan Venkatraman held 7 earlier board appointments: Tata Consultancy Services Limited (Director, 05 Sep 2005 to 10 Jul 2018); E.I.D Parry (India) Limited (Director, 29 Mar 2004 to 19 Mar 2007); Glaxosmithkline Pharmaceuticals Limited (Director, 01 Jan 2001 to 31 Oct 2015); Indegene Limited (Additional Director, 28 Aug 2008 to 29 Sep 2008); Healthium Medtech Limited (Director, 09 Sep 2015 to 22 Jun 2018); and 2 more.